Soleno Therapeutics CFO files initial Form 3

Soleno Therapeutics Inc. filed an initial insider ownership statement for its Chief Financial Officer, Jennifer Fulk.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Soleno Therapeutics Inc. filed an initial insider ownership statement for its Chief Financial Officer, Jennifer Fulk. This Form 3 establishes her reporting status as an officer of the company. The filing does not list any reportable transactions or share holdings at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Soleno Therapeutics (SLNO) Form 3 for Jennifer Fulk show?

The Form 3 shows that Jennifer Fulk is the Chief Financial Officer of Soleno Therapeutics and is now a reporting insider. It serves as an initial ownership statement and does not list any specific transactions or share amounts.

Does the SLNO Form 3 for Jennifer Fulk report any stock transactions?

No, the Form 3 for Jennifer Fulk does not report any stock transactions. It only establishes her status as an officer and insider of Soleno Therapeutics without detailing purchases, sales, or specific share holdings.

What is Jennifer Fulk’s role at Soleno Therapeutics (SLNO) according to the Form 3?

According to the Form 3, Jennifer Fulk serves as Chief Financial Officer of Soleno Therapeutics. This officer title triggers insider reporting obligations, requiring disclosure of her beneficial ownership and future reportable transactions in company securities.

Why is a Form 3 filed for Soleno Therapeutics’ CFO?

A Form 3 is filed to register the CFO as an insider subject to ongoing SEC reporting. For Jennifer Fulk at Soleno Therapeutics, it creates a baseline for future Forms 4 or 5 that will disclose any subsequent transactions in the company’s securities.

Does the SLNO Form 3 include any ownership footnote details?

The Form 3 includes a footnote section, but no substantive footnote details are provided in the available data. There are no additional explanations about indirect ownership, voting power, or related entities disclosed in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/04/2026 - 05:58 PM EST

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fulk Jennifer

(Last)

(First)

(Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF FINANCIAL OFFICER

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Anish Bhatnagar, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR